Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT)

Author:

Longtin Yves12,Gervais Philippe3,Birnie David H4,Wang Jia5,Alings Marco6ORCID,Philippon François3ORCID,Parkash Ratika7,Manlucu Jaimie8,Angaran Paul9ORCID,Rinne Claus10,Coutu Benoit11,Low R Aaron12,Essebag Vidal13ORCID,Morillo Carlos5,Redfearn Damian14,Toal Satish15,Becker Giuliano16,Degrâce Michel17,Thibault Bernard18,Crystal Eugene19ORCID,Tung Stanley20,LeMaitre John21,Sultan Omar22,Bennett Matthew23ORCID,Bashir Jamil20,Ayala-Paredes Felix24,Rioux Leon25,Hemels Martin E W26,Bouwels Leon H R27,Exner Derek V28ORCID,Dorian Paul29,Connolly Stuart J5,Krahn Andrew D23

Affiliation:

1. Jewish General Hospital Sir Mortimer B. Davis, McGill University, Montreal, Quebec, Canada

2. Lady Davis Research Institute, Montreal, Quebec, Canada

3. Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Quebec City, Quebec, Canada

4. University of Ottawa Heart Institute, Ottawa, Ontario, Canada

5. Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada

6. Amphia Ziekenhuis & Working Group on Cardiovascular Research (WCN), Breda, the Netherlands

7. Queen Elizabeth II Health Science Center, Halifax, Nova Scotia, Canada

8. Lawson Health Research Institute, London Health Sciences, Western University, London, Ontario, Canada

9. Department of Medicine, University of Toronto, Division of Cardiology, St. Michael’s Hospital, Toronto, Ontario, Canada

10. St. Mary’s General Hospital, Kitchener, Ontario, Canada

11. Centre hospitalier de l’Université de Montréal (CHUM), University of Montreal, Montreal, Quebec, Canada

12. Chinook Regional Hospital, Lethbridge, Alberta, Canada

13. McGill University Health Center, Montreal, Quebec, Canada

14. Kingston General Hospital, Queen’s University, Kingston, Ontario, Canada

15. Horizon Health Network, Saint John, New Brunswick, Canada

16. Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada

17. Hôtel-Dieu de Lévis, Lévis, Quebec, Canada

18. Montreal Heart Institute, Montreal, Quebec, Canada

19. Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

20. St. Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada

21. Royal Columbian Hospital, New Westminster, British Columbia, Canada

22. Regina General Hospital, Saskatchewan Health Authority, Regina, Saskatchewan, Canada

23. University of British Columbia, Vancouver, British Columbia, Canada

24. Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada

25. Centre de santé et de services sociaux de Rimouski-Neigette (CSSSRN), Rimouski, Quebec, Canada

26. Ziekenhuis Rijnstate, Arnhem, and Radboud University Medical Centre, Nijmegen, the Netherlands

27. Canisius Wilhelmina Ziekenhuis, Nijmegen, the Netherlands

28. Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada

29. Department of Medicine, University of Toronto, Division of Cardiology, St. Michael Hospital, Toronto, Ontario, Canada

Abstract

Abstract Background The Prevention of Arrhythmia Device Infection Trial (PADIT) investigated whether intensification of perioperative prophylaxis could prevent cardiac implantable electronic device (CIED) infections. Compared with a single dose of cefazolin, the perioperative administration of cefazolin, vancomycin, bacitracin, and cephalexin did not significantly decrease the risk of infection. Our objective was to compare the microbiology of infections between study arms in PADIT. Methods This was a post hoc analysis. Differences between study arms in the microbiology of infections were assessed at the level of individual patients and at the level of microorganisms using the Fisher exact test. Results Overall, 209 microorganisms were reported from 177 patients. The most common microorganisms were coagulase-negative staphylococci (CoNS; 82/209 [39.2%]) and S. aureus (75/209 [35.9%]). There was a significantly lower proportion of CoNS in the incremental arm compared with the standard arm (30.1% vs 46.6%; P = .04). However, there was no significant difference between study arms in the frequency of recovery of other microorganisms. In terms of antimicrobial susceptibility, 26.5% of microorganisms were resistant to cefazolin. CoNS were more likely to be cefazolin-resistant in the incremental arm (52.2% vs 26.8%, respectively; P = .05). However, there was no difference between study arms in terms of infections in which the main pathogen was sensitive to cefazolin (77.8% vs 64.3%; P = .10) or vancomycin (90.8% vs 90.2%; P = .90). Conclusions Intensification of the prophylaxis led to significant changes in the microbiology of infections, despite the absence of a decrease in the overall risk of infections. These findings provide important insight on the physiopathology of CIED infections. Trial registration NCT01002911.

Funder

Heart and Stroke Foundation of Canada

Sauder Family and Heart and Stroke Foundation Chair in Cardiology

Paul Brunes Chair in Heart Rhythm Disorders

Canadian Network and Centre for Trials Internationally

Canadian Institutes of Health Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3